Johnson & Johnson vs Pfizer (JNJ vs PFE)
Both trade near 41x earnings; Johnson & Johnson grows sales faster (+5.9% vs -0.4%) and Johnson & Johnson keeps a 16% margin vs 6%. Data Nov 2026.
Quick answer
On today's data (November 19, 2026): Pfizer looks cheaper on P/E: 40.1x against 41.4x for Johnson & Johnson. Johnson & Johnson grows faster: sales +5.9% against -0.4% for Pfizer in the latest quarter. Johnson & Johnson has the better net margin: 16.2% against 6.3% for Pfizer.
This is a snapshot of the numbers, not a recommendation to buy or sell.
Your first analysis is free with a free account, no card.
Short answer
On P/E as of November 19, 2026, Johnson & Johnson is the more expensive of the two: it trades at 41.4x its annual earnings against 40.1x for Pfizer. Johnson & Johnson reports two segments. Innovative Medicine, the larger, sells drugs such as Darzalex, Stelara, Tremfya, Erleada and Carvykti across oncology, immunology and neuroscience. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. What helps read that gap: Johnson & Johnson sales +5.9% against -0.4% for Pfizer in the latest quarter; net margin 16.2% against 6.3%; net debt for Johnson & Johnson: 0.8x EBITDA against 2.0x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.
Johnson & Johnson (JNJ) and Pfizer (PFE) compete in healthcare and pharma. Here are Johnson & Johnson and Pfizer side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Johnson & Johnson or Pfizer.
Johnson & Johnson vs Pfizer: the figures
| Figure | Johnson & Johnson | Pfizer |
|---|---|---|
| Share price | $272.70 (November 18, 2026) | $28.06 (November 18, 2026) |
| Market cap | $656.5 billion | $159.9 billion |
| P/E (TTM) | 41.4x | 40.1x |
| Forward P/E | 23.5x | 9.5x |
| Revenue growth (quarter) | +5.9% | -0.4% |
| Net margin (TTM) | 16.2% | 6.3% |
| Net debt / EBITDA | 0.8x | 2.0x |
| Dividend yield | 1.97% | 6.13% |
| Beta | 0.20 | 0.30 |
Johnson & Johnson and Pfizer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Johnson & Johnson or Pfizer figure is not available, and we never estimate it.
3 key differences between Johnson & Johnson and Pfizer
- Dividend: Pfizer yields 6.13% at today's price and Johnson & Johnson yields 1.97%.
- Profitability: for every 100 of sales, Johnson & Johnson keeps 16.2 as net profit and Pfizer keeps 6.3.
- Size: Johnson & Johnson is worth $656.5 billion on the stock market, about 4.1 times Pfizer ($159.9 billion).
Johnson & Johnson or Pfizer: which fits your profile
- If you want growth: Johnson & Johnson is growing faster today, with sales +5.9% against -0.4% for Pfizer and also trades on a higher P/E (41.4x against 40.1x). Investors who prioritise growth usually accept more volatility; the P/E only shows what you pay today for each unit of the last 12 months' earnings.
- If you want income (dividends): Pfizer pays the higher dividend relative to its price.
- If you prefer caution: Johnson & Johnson has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Pfizer trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Johnson & Johnson nor Pfizer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
Verdict: Johnson & Johnson or Pfizer?
Of the 6 comparable figures in the table, Johnson & Johnson stands out on 4 (sales growth, net margin, less debt over EBITDA and lower volatility (beta)) and Pfizer stands out on 2 (lower P/E and dividend yield). That does not name a winner between Johnson & Johnson and Pfizer: the table is a snapshot of today, not a forecast.
Keep reading free.
Create your free account to continue reading “Johnson & Johnson vs Pfizer (JNJ vs PFE)”.
No card required
Johnson & Johnson vs Pfizer by dimension
Strategy
Johnson & Johnson operates in healthcare and pharma and Pfizer in healthcare and pharma, so they only fight for the same customer when the sector overlaps. By stock-market size, Johnson & Johnson is the larger of the two.
Products and AI
Johnson & Johnson and Pfizer sell different things: Johnson & Johnson reports two segments. And for Pfizer: Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev.
Margins
Johnson & Johnson is more profitable: it keeps 16.2 of every 100 it sells, against 6.3 for Pfizer.
Valuation
Johnson & Johnson trades at the higher P/E (41.4x against 40.1x for Pfizer). A higher P/E is only justified if earnings grow faster.
Risks
Pfizer is the more volatile: beta 0.30 against 0.20 for Johnson & Johnson.
Competitors
Other companies investors compare Johnson & Johnson and Pfizer with: Intuitive Surgical, Medtronic, Thermo Fisher, UnitedHealth. Intuitive Surgical · Medtronic · Thermo Fisher · UnitedHealth
How Johnson & Johnson and Pfizer make money
Johnson & Johnson (JNJ)
Johnson & Johnson reports two segments. Innovative Medicine, the larger, sells drugs such as Darzalex, Stelara, Tremfya, Erleada and Carvykti across oncology, immunology and neuroscience. MedTech sells orthopedic devices through DePuy Synthes, surgical tools, cardiovascular products from Abiomed and Shockwave, and vision care. The U.S. is its largest market. Full Johnson & Johnson analysis.
Pfizer (PFE)
Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. The U.S. is its biggest market. Full Pfizer analysis.
Frequently asked questions: Johnson & Johnson vs Pfizer
What is the difference between Johnson & Johnson and Pfizer?
Johnson & Johnson reports two segments. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. Both are in healthcare and pharma. As of November 19, 2026: P/E 41.4 vs 40.1; net margin 16% vs 6% (Johnson & Johnson vs Pfizer).
Is Johnson & Johnson or Pfizer the better stock?
Choosing between Johnson & Johnson and Pfizer depends on what you are looking for. Johnson & Johnson is growing faster right now, and Pfizer trades on the lower P/E. Fintols does not tell you whether to buy Johnson & Johnson or Pfizer: it shows you the differences so you can decide.
Which pays a higher dividend, Johnson & Johnson or Pfizer?
As of November 19, 2026, Pfizer yields 6.13% and Johnson & Johnson yields 1.97%. Also check how much of their profit Johnson & Johnson and Pfizer pay out: if it is more than they earn, it cannot last.
Which is more expensive, Johnson & Johnson or Pfizer?
On P/E, Johnson & Johnson (41.4x) is more expensive than Pfizer (40.1x) as of November 19, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Which is more profitable, Johnson & Johnson or Pfizer?
On net margin, Johnson & Johnson (16.2%) keeps more of every 100 it sells than Pfizer (6.3%), as of November 19, 2026.
Which has more debt, Johnson & Johnson or Pfizer?
As of November 19, 2026, Pfizer owes 2.0x its EBITDA and Johnson & Johnson owes 0.8x its EBITDA (net debt over EBITDA).
Can I own both Johnson & Johnson and Pfizer?
Yes. Many people spread their money across several companies, such as Johnson & Johnson and Pfizer, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Johnson & Johnson or Pfizer.
To go deeper: Does Johnson & Johnson pay a dividend? and Does Pfizer pay a dividend?.
Related comparisons for Johnson & Johnson and Pfizer
- Intuitive Surgical vs Johnson & Johnson
- Johnson & Johnson vs Medtronic
- Johnson & Johnson vs Merck
- Johnson & Johnson vs Eli Lilly
More companies like Johnson & Johnson and Pfizer: healthcare and pharma stocks. Educational content about Johnson & Johnson and Pfizer, not investment advice.
Full analyses: Johnson & Johnson and Pfizer. Machine-readable summary: llms.txt.
Your first analysis is free with a free account, no card.
Your own analysis of Johnson & Johnson or Pfizer.
Create a free account and run your first full analysis in a minute. No card needed.
- How it makes money
- Valuation scenarios
- What could go wrong
First full analysis free · No card